Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

NSCLC治療薬の世界市場予測

◆タイトル:Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027
◆商品コード:VGAIN7081163
◆調査・発行会社:visiongain
◆発行日:2017年6月
◆ページ数:172
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥374,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、NSCLC治療薬の世界市場について調査・分析し、NSCLC治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・NSCLC治療薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・NSCLC治療薬の世界市場:セグメント別市場分析
・NSCLC治療薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

The Non-Small Cell Lung Cancer (NSCLC) Drugs market is estimated at $7.86bn in 2016 and is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.2% during the full forecast period. In 2016, the chemotherapy segment generated a revenue of $3.28bn and represented 41.7% of the total NSCLC drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 172-page report you will receive 133 charts – all unavailable elsewhere.

The 172-page report provides clear detailed insight into the Non-Small Cell Lung Cancer (NSCLC) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Non-Small Cell Lung Cancer (NSCLC) Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the main therapeutic segments:
• Chemotherapy
• EGFR and ALK Inhibitors
• VEGF / VEGFR Inhibitors
• Immunotherapy

• This report provides revenue forecast to 2027 for the leading drugs in this market:
• Alimta (pemetrexed) by Eli Lilly
• Avastin (bevacizumab) by Roche
• Tarceva (erlotinib) by Roche
• Iressa (gefitinib) by AstraZeneca
• Gilotrif (afatinib) by Boehringer Ingelheim
• Xalkori (crizotinib) by Pfizer
• Abraxane (paclitaxel Protein-Bound) by Celgene
• Taxotere (docetaxel) by Sanofi
• Cyramza (ramucirumab) by Eli Lilly
• Zykadia (ceritinib) by Novartis
• Opdivo (nivolumab) by Bristol-Myers Squibb

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• The US
• Japan
• Germany
• France
• Italy
• Spain
• The UK
• China
• Brazil
• Russia
• India
• Rest of the World

• This report also includes a chapter on R&D which discusses some of the most promising and prominent late-stage candidates

• Our study includes a SWOT analysis of this industry and market

• Our study explores the issues and forces that influence the NSCLC drugs market:
• Genetic mutations allowing for targeted therapies, newer medicines offering improved treatment outcomes
• Treatment protocols by stage and for patient populations – maintenance, second-line and third-line therapies
• Regulators’ views and cost-effectiveness – challenges and opportunities in drug approvals, pricing, reimbursement and healthcare budgets
• Recent approval for the NSCLC indication – expanding treatment options
• Overcoming patent expiries and competition from generic drugs
• Identification of biomarkers for targeted therapies, advancing treatment protocols.

Visiongain’s study is intended for anyone requiring commercial analyses for the Non-Small Cell Lung Cancer (NSCLC) Drugs market. You find data, trends and predictions.

Buy our report today Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other.

【レポートの目次】

1. Report Overview
1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
1.2 Why You Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to NSCLC and its Treatment
2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
2.2 The Three Main Histological Sub-Types of NSCLC
2.3 Genetic Mutations Allow for Targeted Therapies
2.4 Staging of NSCLC
2.5 Treatment Protocols by Stage
2.5.1 Stage 1 or 2
2.5.2 Stage 3
2.5.3 Stage 4: First Line-Therapy
2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
2.5.4 Maintenance Therapy
2.5.5 Second-Line and Third-Line Therapy

3. Leading NSCLC Drugs, 2017-2027
3.1 Alimta (pemetrexed) by Eli Lilly – The Leading NSCLC Therapy
3.1.1 Mechanism of Action
3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
3.1.3 Patent Expiries
3.1.3.1 ‘Method-Of-Use’ Vitamin Dosage Regimen Patent – Alimta’s Saviour from Generic Competition?
3.1.4 NICE Rejects Alimta for Maintenance Therapy
3.1.5 Total Alimta Revenues, 2010-2016
3.1.6 Alimta for NSCLC, 2016
3.1.7 Alimta for NSCLC Forecast, 2017-2027
3.2 Avastin (bevacizumab) – Roche’s Cancer Behemoth is a Leading Presence in NSCLC
3.2.1 Mechanism of Action
3.2.2 Multiple Approved Indications, but NSCLC was one of the First
3.2.3 Growing Discontent with Avastin in NSCLC – Is it Cost-Effective?
3.2.4 Total Avastin Revenues, 2010-2016
3.2.5 Avastin for NSCLC Forecast, 2017-2027
3.3 Tarceva (erlotinib) by Roche
3.3.1 Mechanism of Action
3.3.2 Three of Four Indications are for NSCLC
3.3.3 NICE Changes Mind on Tarceva – and then Changes it Back Again
3.3.4 Total Tarceva Revenues, 2010-2016
3.3.5 Tarceva for NSCLC Forecast, 2017-2027
3.4 Iressa (gefitinib) by AstraZeneca
3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
3.4.2 Iressa NSCLC Revenues, 2010-2016
3.4.3 Iressa for NSCLC Forecast, 2017-2027
3.5 Gilotrif (afatinib) by Boehringer Ingelheim
3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
3.5.3 Gilotrif for NSCLC Forecast, 2017-2027
3.6 Xalkori (crizotinib) by Pfizer
3.6.1 Mechanism of Action
3.6.2 The First Approved ALK Inhibitor
3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
3.6.4 Xalkori NSCLC Revenues, 2012-2016
3.6.5 Xalkori for NSCLC Forecast, 2017-2027
3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
3.7.1 Mechanism of Action
3.7.2 Relatively Recent Approval for NSCLC Indication
3.7.3 Finally Approved for NSCLC in the EU
3.7.4 Total Abraxane Revenues, 2010-2016
3.7.5 Abraxane for NSCLC Forecast, 2017-2027
3.8 Taxotere (docetaxel) by Sanofi
3.8.1 Mechanism of Action and Approved Indications
3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
3.8.3 Total Taxotere Revenues, 2010-2016
3.8.4 Taxotere for NSCLC Forecast, 2017-2027
3.9 Cyramza (ramucirumab) by Eli Lilly
3.9.1 Mechanism of Action
3.9.2 Many Approvals in Quick Succession
3.9.3 Cyramza for NSCLC Forecast, 2017-2027
3.10 Gemzar (gemcitabine) by Eli Lilly
3.11 Zykadia (ceritinib) by Novartis
3.11.1 Mechanism of Action and Recent Approval
3.11.2 Zykadia for NSCLC Forecast, 2017-2027
3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
3.12.1 Mechanism of Action – Works With the Immune System to Fight Cancers
3.12.2 Swift Approvals through FDA Priority Review Programmes
3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
3.12.4 Opdivo for NSCLC Forecast, 2017-2027

4. NSCLC R&D Pipeline, 2017-2027
4.1 Alecensa (alectinib) by Roche
4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
4.1.2 Roche is Inching Closer Towards the All-Important US Approval
4.1.3 Roche receives EU Approval
4.1.4 Seven Ongoing Clinical Trials involving Alectinib in NSCLC
4.1.5 Japanese Revenues and Future Outlook
4.2 Vargatef (nintedanib) by Boehringer Ingelheim
4.2.1 EU Becomes First Region to Approve Vargatef
4.2.2 NICE has a Change of Heart on Vargatef
4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
4.3 AZD9291 by AstraZeneca
4.3.1 Regulatory Approval in the US
4.3.2 Regulatory Approval in the EU
4.3.3 Regulatory Approval in Japan and China
4.3.4 Collaboration with Roche to Develop Companion Diagnostic
4.3.5 Positive Preliminary Results Presented at ASCO 2015
4.3.6 Ongoing Clinical Trials Involving AZD9291 in NSCLC
4.4 Rociletinib (CO-1686) by Clovis Oncology
4.4.1 In a Race to Approval Against AZD9291
4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
4.5 Keytruda (pembrolizumab) by Merck (MSD)
4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
4.6.1 Ganetespib Mechanism of Action
4.6.2 Termination of Ganetespib trial
4.7 Halaven (eribulin) by Eisai
4.7.1 Halaven Mechanism of Action
4.7.2 US Approval for Halaven
4.7.3 EU Approval for Halaven
4.7.4 Clinical Trials Involving Halaven in NSCLC
4.8 Necitumumab by Eli Lilly
4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
4.9 Atezolizumab (MPDL3280A) by Roche
4.9.1 Mechanism of Action
4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
4.9.3 Ongoing Clinical Trials Involving Atezolizumab in NSCLC

5. Global NSCLC Market, 2017-2027
5.1 The Global NSCLC Market Forecast, 2017-2027
5.2 What Factors will Drive Growth in the Global NSCLC Market?
5.3 Growing Ageing Population
5.4 The Identification of Biomarkers for Targeted Therapies
5.5 Dynamic and Lucrative Sector with Strong Pipeline
5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
5.7 What Factors will Restrain Growth in the Global NSCLC Market?
5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
5.11 SWOT Analysis of the Global NSCLC Market

6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market
6.1 Therapeutic Composition of the Market in 2017 Compared to 2027
6.1.1 Therapeutic Segments Forecast, 2017-2027
6.1.2 Chemotherapy Segment Forecast, 2017-2027
6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2017-2027
6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2017-2027
6.1.5 Immunotherapy Segment Forecast, 2017-2027
6.2 Leading National Markets for NSCLC
6.2.1 Regional Composition of the Global Market in 2017, Compared to 2027
6.2.2 Leading Regional Markets for NSCLC Forecast, 2017-2027
6.2.3 US NSCLC Market, 2017-2027
6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
6.2.3.2 US NSCLC Market Forecast, 2017-2027
6.2.4 EU5 NSCLC Market, 2017-2027
6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
6.2.4.2 German NSCLC Market Forecast, 2017-2027
6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
6.2.4.4 French NSCLC Market Forecast, 2017-2027
6.2.4.5 Italian NSCLC Market
6.2.4.6 Italian NSCLC Market Forecast, 2017-2027
6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
6.2.4.8 UK NSCLC Market Forecast, 2017-2027
6.2.4.9 Spanish NSCLC Market
6.2.4.10 Spanish NSCLC Market Forecast, 2017-2027
6.2.5 Japanese NSCLC Market
6.2.5.1 Expansion of the Generics Market is a Key Factor
6.2.5.2 Japanese NSCLC Market Forecast, 2017-2027
6.2.6 BRIC NSCLC Market, 2017-2027
6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
6.2.6.2 China NSCLC Market Forecast, 2017-2027
6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
6.2.6.4 Brazilian NSCLC Market Forecast, 2017-2027
6.2.6.5 Russian NSCLC Market: Punches Below its Weight
6.2.6.6 Russian NSCLC Market Forecast, 2017-2027
6.2.6.7 Indian NSCLC Market: Generics are King
6.2.6.8 Indian NSCLC Market Forecast, 2017-2027

7. Conclusions from our Research and Analysis
7.1 How Will Revenues Change over the Forecast Period?
7.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
7.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
7.4 Concluding Remarks

Appendices
Visiongain’s Bespoke Research Service
Some Associated Reports
Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 1.1 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Example NSCLC First-Line Therapy Options for the Different Patient Populations
Table 3.1 FDA-Approved Indications for Alimta, 2004-2009
Table 3.2 Patent Expiries for Alimta, 2015-2022
Table 3.3 Total Alimta Revenues ($bn), AGR (%), CAGR (%), 2010-2016
Table 3.4 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.5 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.6 FDA-Approved Indications for Avastin, 2004-2014
Table 3.7 Total Avastin Revenues ($bn), AGR (%), CAGR (%), 2010-2016
Table 3.8 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.9 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.10 FDA-Approved Indications for Tarceva, 2004-2013
Table 3.11 Total Tarceva Revenues ($bn), AGR (%), CAGR (%), 2010-2016
Table 3.12 Tarceva NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.13 Tarceva for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.14 Total Iressa Revenues ($bn), 2010-2016
Table 3.15 Iressa NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.16 Iressa for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.17 Gilotrif NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.18 Gilotrif for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.19 Total Xalkori Revenues ($bn), AGR (%), CAGR (%), 2012-2016
Table 3.20 Xalkori NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.21 Xalkori for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.22 FDA-Approved Indications for Abraxane, 2005-2013
Table 3.23 Total Abraxane Revenues ($bn), AGR (%), CAGR (%), 2010-2016
Table 3.24 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.25 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.26 FDA-Approved Indications for Taxotere, 1999-2006
Table 3.27 Total Taxotere Revenues ($bn), AGR (%), CAGR (%), 2010-2016
Table 3.28 Taxotere NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.29 Taxotere for NSCLC Forecast: Revenues ($bn), AGR (%),CAGR (%), 2021-2027
Table 3.30 FDA-Approved Indications for Cyramza, 2014-2015
Table 3.31 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.32 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.33 FDA-Approved Indications for Abraxane, 1996-2006
Table 3.34 Zykadia NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.35 Zykadia for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 3.36 Opdivo NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 3.37 Opdivo for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 4.1 Currently Ongoing Clinical Trials Involving Alectinib in NSCLC
Table 4.2 Selected Ongoing Clinical Trials Involving Vargatef in NSCLC
Table 4.3 Selected Ongoing Clinical Trials Involving AZD9291 in NSCLC
Table 4.4 Ongoing Clinical Trials Involving Rociletinib in NSCLC
Table 4.5 Selected Ongoing Clinical Trials Involving Keytruda in NSCLC
Table 4.6 Ongoing Clinical Trials Involving Ganetespib in NSCLC
Table 4.7 Clinical Trials Involving Halaven in NSCLC
Table 4.8 Selected Ongoing Clinical Trials Involving Necitumumab in NSCLC
Table 4.9 Ongoing Clinical Trials Involving Atezolizumab in NSCLC
Table 5.1 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
Table 5.2 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
Table 6.1 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.2 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.3 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.4 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.6 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.7 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.8 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.9 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2014-2020
Table 6.10 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.11 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.12 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.13 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.14 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.15 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%),2014-2020
Table 6.16 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
Table 6.17 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.18 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.19 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.20 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
Table 6.21 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.22 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
Table 6.23 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2014-2020
Table 6.24 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
Table 6.25 Japanese NSCLC Market:Revenues ($bn), AGR (%),CAGR (%),Market Share (%), 2014-2020
Table 6.26 Japanese NSCLC Market: Revenues ($bn),AGR (%),CAGR (%),Market Share (%), 2021-2027
Table 6.27 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2014-2020
Table 6.28 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
Table 6.29 Brazilian NSCLC Market: Revenues ($bn),AGR (%),CAGR (%),Market Share (%), 2014-2020
Table 6.30 Brazilian NSCLC Market: Revenues ($bn),AGR (%),CAGR (%),Market Share (%), 2021-2027
Table 6.31 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2014-2020
Table 6.32 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
Table 6.33 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.34 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027

List of Figures
Figure 2.1 Example Adjuvant Chemotherapy Regimens for NSCLC in Stage 1 or Stage 2
Figure 2.2 Example Chemotherapy Regimens for Use in Concurrent Chemotherapy / Radiation in Stage 3 NSCLC
Figure 2.3 Example Chemotherapy Regimens for use in Stage 4 NSCLC
Figure 3.1 Total Alimta Revenues ($bn), 2010-2016
Figure 3.2 Alimta for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.3 Total Avastin Revenues ($bn), 2010-2016
Figure 3.4 Avastin for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.5 Total Tarceva Revenues ($bn), 2010-2016
Figure 3.6 Tarceva for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.7 Total Iressa Revenues ($bn), 2010-2016
Figure 3.8 Iressa Revenues Regional Breakdown: Revenues ($bn), Market Share (%), 2016
Figure 3.9 Iressa for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.10 Gilotrif for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.11 Total Xalkori Revenues ($bn), 2012-2016
Figure 3.12 Xalkori for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.13 Total Abraxane Revenues ($bn), 2010-2016
Figure 3.14 Abraxane for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.15 Total Taxotere Revenues ($bn), 2010-2016
Figure 3.16 Taxotere for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.17 Cyramza for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.18 Zykadia for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 3.19 Opdivo for NSCLC Forecast: Revenues ($bn), 2017-2027
Figure 5.1 Global NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 5.2 SWOT Analysis of Global NSCLC Market, 2017
Figure 6.1 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2017
Figure 6.2 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2027
Figure 6.3 Therapeutic Segments within the NSCLC Market: Revenues ($bn), 2017-2027
Figure 6.4 Chemotherapy Segment: Revenues ($bn), 2017-2027
Figure 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), 2017-2027
Figure 6.6 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), 2017-2027
Figure 6.7 Immunotherapy Segment: Revenues ($bn), 2017-2027
Figure 6.8 Regional Composition of the Global NSCLC Market: Revenues ($bn),Market Share (%), 2017
Figure 6.9 Regional Composition of the Global NSCLC Market: Revenues ($bn),Market Share (%), 2027
Figure 6.10 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), 2017-2027
Figure 6.11 US NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.12 German NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.13 French NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.14 Italian NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.15 UK NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.16 Spanish NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.17 Japanese NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.18 Chinese NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.19 Brazilian NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.20 Russian NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 6.21 Indian NSCLC Market Forecast: Revenues ($bn), 2017-2027
Figure 7.1 Global NSCLC Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2017-2027
Figure 7.2 Breakdown by Submarket: Revenues ($bn), 2017-2027
Figure 7.3 Leading National Markets: Revenues ($bn), 2017
Figure 7.4 Leading National Markets: Revenues ($bn), 2027

【レポートのキーワード】

NSCLC治療薬

★調査レポート[NSCLC治療薬の世界市場予測] ( Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027 / VGAIN7081163) 販売に関する免責事項
[NSCLC治療薬の世界市場予測] ( Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027 / VGAIN7081163) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆